Associated Genetic Biomarkers
ERCC3 Nonsense is present in 0.07% of AACR GENIE cases, with endometrial endometrioid adenocarcinoma, lung adenocarcinoma, colon adenocarcinoma, breast invasive lobular carcinoma, and cutaneous melanoma having the greatest prevalence .
ERCC3 Nonsense serves as an inclusion eligibility criterion in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains ERCC3 Nonsense as an inclusion criterion, 1 is phase 2 (1 open).
Trials with ERCC3 Nonsense in the inclusion eligibility criteria most commonly target prostate adenocarcinoma .
Rucaparib is the most frequent therapy in trials with ERCC3 Nonsense as an inclusion criteria .
Significance of ERCC3 Nonsense in Diseases
Prostate Adenocarcinoma +
ERCC3 is altered in 0.93% of prostate adenocarcinoma patients .
ERCC3 Nonsense is an inclusion criterion in 1 clinical trial for prostate adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC3 Nonsense and prostate adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.